vs
HAEMONETICS CORP（HAE）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是LiveRamp Holdings, Inc.的1.6倍（$339.0M vs $212.2M），LiveRamp Holdings, Inc.净利率更高（18.8% vs 13.2%，领先5.6%），LiveRamp Holdings, Inc.同比增速更快（8.6% vs -2.7%），过去两年LiveRamp Holdings, Inc.的营收复合增速更高（11.1% vs 0.4%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
HAE vs RAMP — 直观对比
营收规模更大
HAE
是对方的1.6倍
$212.2M
营收增速更快
RAMP
高出11.3%
-2.7%
净利率更高
RAMP
高出5.6%
13.2%
两年增速更快
RAMP
近两年复合增速
0.4%
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $212.2M |
| 净利润 | $44.7M | $39.9M |
| 毛利率 | 59.7% | 71.9% |
| 营业利润率 | 19.9% | 18.6% |
| 净利率 | 13.2% | 18.8% |
| 营收同比 | -2.7% | 8.6% |
| 净利润同比 | 19.3% | 255.7% |
| 每股收益（稀释后） | $0.95 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAERAMP
| Q4 25 | $339.0M | $212.2M | ||
| Q3 25 | $327.3M | $199.8M | ||
| Q2 25 | $321.4M | $194.8M | ||
| Q1 25 | $330.6M | $188.7M | ||
| Q4 24 | $348.5M | $195.4M | ||
| Q3 24 | $345.5M | $185.5M | ||
| Q2 24 | $336.2M | $176.0M | ||
| Q1 24 | — | $171.9M |
净利润HAERAMP
| Q4 25 | $44.7M | $39.9M | ||
| Q3 25 | $38.7M | $27.4M | ||
| Q2 25 | $34.0M | $7.7M | ||
| Q1 25 | $58.0M | $-6.3M | ||
| Q4 24 | $37.5M | $11.2M | ||
| Q3 24 | $33.8M | $1.7M | ||
| Q2 24 | $38.4M | $-7.5M | ||
| Q1 24 | — | $-5.4M |
毛利率HAERAMP
| Q4 25 | 59.7% | 71.9% | ||
| Q3 25 | 59.5% | 70.2% | ||
| Q2 25 | 59.8% | 70.1% | ||
| Q1 25 | 58.4% | 69.3% | ||
| Q4 24 | 55.5% | 71.9% | ||
| Q3 24 | 54.2% | 72.4% | ||
| Q2 24 | 52.0% | 70.6% | ||
| Q1 24 | — | 72.2% |
营业利润率HAERAMP
| Q4 25 | 19.9% | 18.6% | ||
| Q3 25 | 17.9% | 10.7% | ||
| Q2 25 | 16.8% | 3.7% | ||
| Q1 25 | 21.6% | -6.1% | ||
| Q4 24 | 16.9% | 7.5% | ||
| Q3 24 | 15.0% | 4.0% | ||
| Q2 24 | 11.8% | -3.0% | ||
| Q1 24 | — | -8.3% |
净利率HAERAMP
| Q4 25 | 13.2% | 18.8% | ||
| Q3 25 | 11.8% | 13.7% | ||
| Q2 25 | 10.6% | 4.0% | ||
| Q1 25 | 17.5% | -3.3% | ||
| Q4 24 | 10.8% | 5.7% | ||
| Q3 24 | 9.8% | 0.9% | ||
| Q2 24 | 11.4% | -4.3% | ||
| Q1 24 | — | -3.1% |
每股收益（稀释后）HAERAMP
| Q4 25 | $0.95 | $0.62 | ||
| Q3 25 | $0.81 | $0.42 | ||
| Q2 25 | $0.70 | $0.12 | ||
| Q1 25 | $1.17 | $-0.10 | ||
| Q4 24 | $0.74 | $0.17 | ||
| Q3 24 | $0.66 | $0.03 | ||
| Q2 24 | $0.74 | $-0.11 | ||
| Q1 24 | — | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $403.4M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $911.5M | $962.3M |
| 总资产 | $2.5B | $1.3B |
| 负债/权益比越低杠杆越低 | 1.34× | — |
8季度趋势，按日历期对齐
现金及短期投资HAERAMP
| Q4 25 | $363.4M | $403.4M | ||
| Q3 25 | $296.4M | $376.9M | ||
| Q2 25 | $292.9M | $371.1M | ||
| Q1 25 | $306.8M | $420.8M | ||
| Q4 24 | $320.8M | $384.3M | ||
| Q3 24 | $299.3M | $348.4M | ||
| Q2 24 | $344.4M | $342.7M | ||
| Q1 24 | — | $368.9M |
总债务HAERAMP
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益HAERAMP
| Q4 25 | $911.5M | $962.3M | ||
| Q3 25 | $849.2M | $943.8M | ||
| Q2 25 | $882.3M | $947.8M | ||
| Q1 25 | $820.8M | $948.9M | ||
| Q4 24 | $906.9M | $957.7M | ||
| Q3 24 | $878.9M | $932.1M | ||
| Q2 24 | $905.4M | $951.9M | ||
| Q1 24 | — | $949.1M |
总资产HAERAMP
| Q4 25 | $2.5B | $1.3B | ||
| Q3 25 | $2.4B | $1.2B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.5B | $1.3B | ||
| Q4 24 | $2.5B | $1.3B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.5B | $1.2B | ||
| Q1 24 | — | $1.2B |
负债/权益比HAERAMP
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | — |
| 自由现金流经营现金流 - 资本支出 | $87.2M | — |
| 自由现金流率自由现金流/营收 | 25.7% | — |
| 资本支出强度资本支出/营收 | 1.9% | 0.1% |
| 现金转化率经营现金流/净利润 | 2.09× | — |
| 过去12个月自由现金流最近4个季度 | $308.1M | — |
8季度趋势，按日历期对齐
经营现金流HAERAMP
| Q4 25 | $93.6M | — | ||
| Q3 25 | $111.3M | $57.4M | ||
| Q2 25 | $17.4M | $-15.8M | ||
| Q1 25 | $116.6M | — | ||
| Q4 24 | $43.8M | $45.1M | ||
| Q3 24 | $48.8M | $55.6M | ||
| Q2 24 | $-27.4M | $-9.3M | ||
| Q1 24 | — | — |
自由现金流HAERAMP
| Q4 25 | $87.2M | — | ||
| Q3 25 | $106.3M | $56.8M | ||
| Q2 25 | $13.6M | $-16.2M | ||
| Q1 25 | $100.9M | — | ||
| Q4 24 | $35.2M | $44.8M | ||
| Q3 24 | $39.4M | $55.4M | ||
| Q2 24 | $-33.1M | $-9.6M | ||
| Q1 24 | — | — |
自由现金流率HAERAMP
| Q4 25 | 25.7% | — | ||
| Q3 25 | 32.5% | 28.4% | ||
| Q2 25 | 4.2% | -8.3% | ||
| Q1 25 | 30.5% | — | ||
| Q4 24 | 10.1% | 22.9% | ||
| Q3 24 | 11.4% | 29.8% | ||
| Q2 24 | -9.8% | -5.4% | ||
| Q1 24 | — | — |
资本支出强度HAERAMP
| Q4 25 | 1.9% | 0.1% | ||
| Q3 25 | 1.5% | 0.3% | ||
| Q2 25 | 1.2% | 0.2% | ||
| Q1 25 | 4.7% | 0.2% | ||
| Q4 24 | 2.5% | 0.1% | ||
| Q3 24 | 2.7% | 0.1% | ||
| Q2 24 | 1.7% | 0.1% | ||
| Q1 24 | — | 1.0% |
现金转化率HAERAMP
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | 2.09× | ||
| Q2 25 | 0.51× | -2.04× | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | 4.02× | ||
| Q3 24 | 1.44× | 32.10× | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
RAMP
暂无分部数据
